Drug Testing Methodology Sample Clauses

Drug Testing Methodology a. The testing or processing phase shall consist of: (i) Initial screening test; (ii) Confirmation test-if the initial screen testing is positive. b. The urine sample is first tested using the initial drug screening procedure. An initial positive test result will not be considered conclusive; rather, it will be classified as “confirmation pending.” Notification of test results to the supervisor or other departmental designee shall be held until the confirmation test results are obtained and verified by the MRO. c. A specimen testing positive will undergo an additional confirmatory test. The confirmation procedure shall be technologically different and more sensitive than the initial screening test. d. The drug screening tests selected shall be capable of identifying marijuana, cocaine and every major drug of abuse, including heroin, amphetamines and barbiturates. Personnel utilized for testing will be qualified to collect urine samples, or adequately trained in collection procedures. e. Concentrations of a drug at or about the following levels shall be considered a positive test result when using the initial immunoassay drug screening test: (i) Initial Test Standards. The initial test shall use an immunoassay which meets the requirements of the Food and Drug Administration for commercial distribution. The following initial cutoff levels shall be used when screening specimens to determine whether negative or positive for these classes of drugs: SKBL Analyte Initial Test Level (ng/ml) Marijuana 50 ng/ml Cocaine 300 ng/ml Opiates 2000 ng/ml Phencyclidine 25 ng/ml Amphetamine 1000 ng/ml Some specimens may be subjected to initial testing by methods other than immunoassays, where the latter are unavailable for detection of specific drugs of special concern. (ii) Confirmatory Test Standards. All specimens identified as positive on the initial screening test shall be confirmed using gas chromatography/mass spectrometry (GC/MS) techniques and by quantitative analysis at the cutoff levels listed below: SKBL Analyte Initial Test Level (ng/ml)_ Marijuana 15 ng/ml Cocaine 150 ng/ml Opiates: Morphine 2000 ng/ml Codeine 2000 ng/ml Phencyclidine 5 ng/ml Amphetamine 500 ng/ml
Sample 1Sample 2Sample 3See All (19)
AutoNDA by SimpleDocs
Drug Testing Methodology. 1. The testing or processing phase shall consist of a two-step procedure. a. Initial screening test.
Sample 1Sample 2Sample 3See All (14)
Drug Testing Methodology. 1. The testing or processing phase shall consist of a two- step procedure: a. initial screening test b. confirmation test 2. The urine sample is first tested using the initial drug screening procedure. An initial positive test result will not be considered conclusive; rather, it will be classified as "confirmation pending." Notification of test results to the supervisor or other departmental designee shall be held until the confirmation test results are obtained and verified by the M.R.O. 3. A specimen testing positive will undergo an additional confirmatory test. The confirmation procedure shall be technologically different and more sensitive than the initial screening test. 4. The drug screening tests selected shall be capable of identifying marijuana, cocaine and every major drug of abuse including heroin, amphetamines and barbiturates. Personnel utilized for testing will be qualified to collect urine samples, or adequately trained in collection procedures. 5. Concentrations of a drug at or about the following levels shall be considered a positive test result when using the initial immunoassay drug screening test: Initial Test Level (ng/ ml) Marijuana metabolite 100 Cocaine metabolite 300 Opiate metabolite 300* Phencyclidine 25 Amphetamines 1000 Barbiturates 300 *25ng/ml if immunoassay-specific for free morphine. Concentrations of a drug at or above the following levels shall be considered a positive test result when performing a confirmatory CG/MS test on a urine specimen that tested positive using a technologically different test than the initial screening method: Confirmatory Test Level Marijuana metabolite 15* Cocaine metabolite 150** Opiates: Morphine 300+ Codeine 300+ Phencyclidine 00 Xxxxxxxxxxxx Xxxxxxxxxxx 500 Methamphetamine 500 * Delta-9-tetrahydrocannabinol-9-carboxylic acid ** Benzoylecgonine + 25ng/ ml if immunoassay-specific for free morphine Barbiturates 300 6. The laboratory selected to conduct the analysis shall be experienced and capable of quality control, documentation, chain-of-custody, technical expertise and demonstrated proficiency in urinalysis. 7. Employees having negative drug test results shall receive a memorandum stating that no illegal drugs were found. A copy of the letter will be placed in the Employee's personnel file upon the Employee's request. 8. Any employee who interferes with the testing process or breaches the confidentiality of test results shall be subject to discipline.
Sample 1Sample 2See All (7)
Drug Testing Methodology. 1. The testing or processing phase shall consist of a two-step procedure: a. Initial screening test, and b. Confirmation test. 2. The urine sample is first tested using the initial drug screening procedure. An initial positive test result will not be considered conclusive; rather, it will be classified as "confirmation pending." Notification of test results to the Deputy Chief shall be held until the confirmation test results are obtained. 3. A specimen testing positive will undergo an additional confirmatory test. The confirmation procedure shall be technologically different and more sensitive than the initial screening test and shall be performed using gas chromatography/mass spectrometry analysis. 4. The drug screening tests selected shall be capable of identifying marijuana, cocaine, and every major drug of abuse including heroin, amphetamine and barbiturates. 5. Concentrations of a drug at or above the following levels shall be considered a positive test result when using the initial immunoassay drug screening test: Initial Test Level (ng/ml) Marijuana metabolite 100 Cocaine metabolite 300 Opiate metabolite 2,000 Phencyclidine 25 Amphetamines 1,000 Concentrations of a drug at or above the following levels shall be considered a positive test result when performing a confirmation GC/MS test on a urine specimen that tested positive using a technologically different initial screening method: Confirmatory Test Level (ng/ml) Marijuana metabolite ................................................ 15 (1) Cocaine metabolite .................................................... 150 (2) Opiates: (1) Delta-9-tetrahydrocannabinol-9-carboxylic acid
Sample 1Sample 2Sample 3See All (6)
Drug Testing Methodology. 1148 a) The testing or processing phase shall consist of a two-step procedure: 1149 i. Initial screening test as defined in 34.4.5(b). (All employees shall receive 1150 the same initial screening test.) 1151 ii. Confirmation test (GCMS) 1152 b) The urine sample is first tested using the initial drug screening procedure. An 1153 initial positive test result will not be considered conclusive; rather, it will be 1154 classified as “confirmation pending.” Notification of test results to the Chief 1155 shall be held until the confirmation test results are obtained.
Sample 1Sample 2See All (4)
Drug Testing Methodology. 1. The testing or processing phase shall consist of a two-step procedure: a. initial screening test b. confirmation test 2. The urine sample is first tested using the initial drug screening procedure. An initial positive test result will not be considered conclusive; rather, it will be classified as "confirmation pending." Notification of test results to the supervisor or other departmental designee shall be held until the confirmation test results are obtained and verified by the M.R.O. 3. A specimen testing positive will undergo an additional confirmatory test. The confirmation procedure shall be technologically different and more sensitive than the initial screening test. 4. The drug screening tests selected shall be capable of identifying marijuana, cocaine and every major drug of abuse including heroin, amphetamines and barbiturates. Personnel utilized for testing will be certified as qualified to collect urine sample or adequately trained in collection procedures. 5. Concentrations of a drug at or about the following levels shall be considered a positive test result when using the initial immunoassay drug screening test: Marijuana metabolite . . . . . . . . . . 100 Cocaine metabolite . . . . . . . . . . . 300 Opiate metabolite. . . . . . . . . . . . 300* Phencyclidine. . . . . . . . . . . . . . 25 Amphetamines . . . . . . . . . . . . . . 1000 Barbiturates . . . . . . . . . . . . . . 300 *25ng/ml if immunoassay-specific for free morphine. Concentrations of a drug at or above the following levels shall be considered a positive test result when performing a confirmatory CG/MS test on a urine specimen that tested positive using a technologically different test than the initial screening method: Confirmatory Test Level Marijuana metabolite . . . . . . . . . . 15* Cocaine metabolite . . . . . . . . . . . 150** Opiates: Morphine. . . . . . . . . . . . . . 300+ Codeine . . . . . . . . . . . . . . 300+ Phencyclidine. . . . . . . . . . . . . . 25 Amphetamines Amphetamine . . . . . . . . . . . . 500 Methamphetamine . . . . . . . . . . 500 * Delta-9-tetrahydrocannabinol-9-carboxylic acid ** Benzoylecgonine + 25ng/ml if immunoassay-specific for free morphine
Sample 1Sample 2See All (4)
Drug Testing Methodology. 1. The testing or processing phase shall consist of a two-step procedure: a. Initial screening test, and b. Confirmation test. 2. The urine sample is first tested using the initial drug screening procedure. An initial positive test result will not be considered conclusive; rather, it will be classified as "confirmation pending." Notification of test results to the supervisor or other departmental designee shall be held until the confirmation test results are obtained. 3. A specimen-testing positive will undergo an additional confirmatory test. The confirmation procedure shall be technologically different and more sensitive than the initial screening test. 4. The drug screening tests selected shall be capable of identifying marijuana, cocaine, and every major drug of abuse including heroin, amphetamine and barbiturates. Personnel utilized for testing will be certified as qualified to collect urine samples or adequately trained in collection procedures. 5. Concentrations of a drug at or above the following levels shall be considered a positive test result when using the initial immunoassay drug screening test: Marijuana metabolite 100 Cocaine metabolite 300 Opiate metabolites 3001 Phencyclidine 25 Amphetamines 1000 125ng/m1 if immunoassay specific for free morphine Concentrations of a drug at or above the following levels shall be considered a positive test result when performing a confirmatory GC/MS Test on a urine specimen that tested positive using a technologically different initial screening method Marijuana metabolite 152 Cocaine metabolite Opiates: 1503 Morphine *300 Codeine *300 Phencyclidine 25 Amphetamines: Amphetamine 500 Methamphetamine 500 2 Delta-9-tetrahydrocannabino1-9-carboxylic acid 3 Benzoylecgonine 6. The laboratory selected to conduct the analysis shall be experienced and capable of quality control, documentation, chain-of-custody, technical expertise, and demonstrated proficiency in urinalysis. 7. Employees having negative drug test results shall receive a memorandum stating that no illegal drugs were found. If the employee requests such, a copy of the letter will be placed in the employee's personnel file. 8. Any employee who breaches the confidentiality of testing information shall be subject to discipline.
Sample 1
AutoNDA by SimpleDocs
Drug Testing Methodology. 24 1. The testing or processing phase shall consist of a two step procedure. 25 A. Initial screening test. 26 B. Confirmation test. 27 2. The urine sample is first tested using the initial drug screening procedure. 28 The laboratory will not release a positive screening result to the City of 29 Mequon until it has been confirmed by alternate more specific methods 30 (GC/MS). 1 3. A specimen testing positive will undergo an additional confirmatory test.
Sample 1
Drug Testing Methodology. 1. The testing or processing phase shall consist of: a. initial screening test; b. confirmation test -- if the initial screening test is positive. 2. The urine sample is first tested using the initial drug screening procedure. An initial positive test result will not be considered conclusive; rather, it will be classified as "confirmation pending." Notification of test results to the supervisor or other departmental designee shall be held until the confirmation test results are obtained and verified by the MRO. 3. A specimen testing positive will undergo an additional confirmatory test. The confirmation procedure shall be technologically different and more sensitive than the initial screening test. 4. The drug screening tests selected shall be capable of identifying marijuana, cocaine and every major drug of abuse including heroin, phencyclidine, amphetamines, and barbiturates. Personnel utilized for testing will be qualified to collect urine samples, or adequately trained in collection procedures. 5. Concentrations of a drug at or about the following levels shall be considered a positive test result when using the initial immunoassay drug screening test: 6. Type of drug or metabolite, initial test and confirmation test levels shall be as provided in 49 CFR Part 40.87 (attached). These cutoff levels are subject to change by the Department of Health and Human Services as advances in technology or other considerations warrant identification of these substances at other concentrations. If these cutoff levels change in the future, the matter will be discussed with the labor associations prior to any amendment of the department’s general order. 7. The laboratory selected to conduct the analysis shall be experienced and capable of assuring quality control, documentation, chain-of-custody, technical expertise, and demonstrated proficiency in urinalysis. 8. Employees having negative drug test results shall receive a memorandum stating that no illegal drugs were found. A copy of the letter will be placed in the employee’s personnel file upon the employee’s request. 9. Any employee who interferes with the testing process or breaches the confidentiality of test results shall be subject to discipline.
Sample 1

Related to Drug Testing Methodology

  • Drug Testing (A) The state and the PBA agree to drug testing of employees in accordance with section 112.0455, F.S., the Drug-Free Workplace Act. (B) All classes covered by this Agreement are designated special risk classes for drug testing purposes. Special risk means employees who are required as a condition of employment to be certified under Chapter 633 or Chapter 943, F.S. (C) An employee shall have the right to grieve any disciplinary action taken under section 112.0455, the Drug-Free Workplace Act, subject to the limitations on the grievability of disciplinary actions in Article 10. If an employee is not disciplined but is denied a demotion, reassignment, or promotion as a result of a positive confirmed drug test, the employee shall have the right to grieve such action in accordance with Article 6.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • Loop Testing/Trouble Reporting 2.1.6.1 Telepak Networks will be responsible for testing and isolating troubles on the Loops. Telepak Networks must test and isolate trouble to the BellSouth portion of a designed/non-designed unbundled Loop (e.g., UVL-SL2, UCL-D, UVL-SL1, UCL-ND, etc.) before reporting repair to the UNE Customer Wholesale Interconnection Network Services (CWINS) Center. Upon request from BellSouth at the time of the trouble report, Telepak Networks will be required to provide the results of the Telepak Networks test which indicate a problem on the BellSouth provided Loop. 2.1.6.2 Once Telepak Networks has isolated a trouble to the BellSouth provided Loop, and had issued a trouble report to BellSouth on the Loop, BellSouth will take the actions necessary to repair the Loop if a trouble actually exists. BellSouth will repair these Loops in the same time frames that BellSouth repairs similarly situated Loops to its End Users. 2.1.6.3 If Telepak Networks reports a trouble on a non-designed or designed Loop and no trouble actually exists, BellSouth will charge Telepak Networks for any dispatching and testing (both inside and outside the CO) required by BellSouth in order to confirm the Loop’s working status. 2.1.6.4 In the event BellSouth must dispatch to the end-user’s location more than once due to incorrect or incomplete information provided by Telepak Networks (e.g., incomplete address, incorrect contact name/number, etc.), BellSouth will xxxx Xxxxxxx Networks for each additional dispatch required to repair the circuit due to the incorrect/incomplete information provided. BellSouth will assess the applicable Trouble Determination rates from BellSouth’s FCC or state tariffs.

  • Laboratory Testing All laboratories selected by UPS Freight for analyzing Controlled Substances Testing will be HHS certified.

  • Claims Review Methodology ‌‌ a. C laims Review Population. A description of the Population subject‌‌ to the Quarterly Claims Review.

  • Power Factor Design Criteria Developer shall design the Large Generating Facility to maintain an effective power delivery at demonstrated maximum net capability at the Point of Interconnection at a power factor within the range established by the Connecting Transmission Owner on a comparable basis, until NYISO has established different requirements that apply to all generators in the New York Control Area on a comparable basis. The Developer shall design and maintain the plant auxiliary systems to operate safely throughout the entire real and reactive power design range. The Connecting Transmission Owner shall not unreasonably restrict or condition the reactive power production or absorption of the Large Generating Facility in accordance with Good Utility Practice.

  • Random Testing Notwithstanding any provisions of the Collective Agreement or any special agreements appended thereto, section 4.6 of the Canadian Model will not be applied by agreement. If applied to a worker dispatched by the Union, it will be applied or deemed to be applied unilaterally by the Employer. The Union retains the right to grieve the legality of any imposition of random testing in accordance with the Grievance Procedure set out in this Collective Agreement.

  • Follow-up Testing An employee shall submit to unscheduled follow-up drug and/or alcohol testing if, within the previous 24-month period, the employee voluntarily disclosed drug or alcohol problems, entered into or completed a rehabilitation program for drug or alcohol abuse, failed or refused a preappointment drug test, or was disciplined for violating the provisions of this Agreement and Employer work rules. The Employer may require an employee who is subject to follow-up testing to submit to no more than six unscheduled drug or alcohol tests within any 12 month period.

  • Service Providing Methodology 1.3.1 Party A and Party B agree that during the term of this Agreement, where necessary, Party B may enter into further service agreements with Party A or any other party designated by Party A, which shall provide the specific contents, manner, personnel, and fees for the specific services. 1.3.2 To fulfill this Agreement, Party A and Party B agree that during the term of this Agreement, where necessary, Party B may enter into equipment or property leases with Party A or any other party designated by Party A which shall permit Party B to use Party A’s relevant equipment or property based on the needs of the business of Party B. 1.3.3 Party B hereby grants to Party A an irrevocable and exclusive option to purchase from Party B, at Party A’s sole discretion, any or all of the assets and business of Party B, to the extent permitted under PRC law, at the lowest purchase price permitted by PRC law. The Parties shall then enter into a separate assets or business transfer agreement, specifying the terms and conditions of the transfer of the assets.

  • Product Testing No later than [**] prior to a scheduled Delivery ARIAD US shall send to ARIAD SWISSCO the Delivery Documents for review. Following such review, unless within [**] of receipt of the Delivery Documents ARIAD SWISSCO gives written notice of rejection of the Product to be delivered, stating the reasons for such rejection, the Delivery shall proceed, and both Parties shall organize the same. Upon arrival at ARIAD SWISSCO nominated site it shall visually inspect the shipment of the Product to identify any damage to the external packaging. ARIAD SWISSCO may reject any shipment (or portion thereof) of the Product that is damaged by providing to ARIAD US reasonable evidence of damage within [**] after Delivery of such Product. If ARIAD SWISSCO does not so reject any shipment (or portion thereof) of the Product within [**] of Delivery of such Product, ARIAD SWISSCO shall be deemed to have accepted such shipment of the Product; provided, however, that in the case of the Product having any Latent Defect, ARIAD SWISSCO shall notify ARIAD US promptly once it becomes aware that a Product contains a Latent Defect and subsequently may reject such Product by giving written notice to ARIAD US of ARIAD SWISSCO’s rejection of such Product and shipping a representative sample of such Product or other evidence of Non-Conformance to ARIAD US within [**] after becoming aware of such Latent Defect, which notice shall include a description of the Latent Defect.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!